Claims

1. Oral dosage form for proton pump antagonists (APA) comprising an effective amount of a proton pump antagonist together with excipients, where the proton pump antagonist is stabilized in the dosage form by one or more basic excipients.

2. Dosage form according to Claim 1, wherein the basic excipient is present in finely divided form and thoroughly mixed with the proton pump antagonist.

3. Dosage form according to Claim 1 or 2, characterized in that excipients which, on oral intake of the dosage form, bring about rapid disintegration of the dosage form, and, where appropriate, further excipients, are additionally present.

4. Dosage form according to Claim 1 to 3, characterized in that the dosage form is selected from the group of tablets, coated tablets, pellets, microtablets in capsules and granules in capsules.

5. Dosage form according to Claim 4, characterized in that it comprises coated tablets.

6. Dosage form according to Claim 3, characterized in that it comprises a rapidly disintegrating dosage form with immediate release of the active ingredient (immediate release solid oral dosage form).

7. Dosage form according to Claim 3, characterized in that it comprises a rapidly disintegrating dosage form with immediate release of the active ingredient (immediate release solid oral dosage form), and the dosage form shows a disintegration of not more than 5 minutes under the test conditions described for „Dispersible Tablets" in the European Pharmacopoeia 4th edition.

8. Dosage form according to Claim 3, characterized in that it comprises a rapidly disintegrating dosage form with immediate release of the active ingredient (immediate release solid oral dosage form), and the dosage form shows a disintegration within 3 minutes under the test conditions described for „Dispersible Tablets" in the European Pharmacopoeia 4th edition.

9. Dosage form according to Claim 7, characterized that it shows a release of active ingredient of greater than or equal to 85% after 15 minutes in 0.1 N hydrochlorid acid.

10. Dosage form according to Claim 3, characterized in that one or more substances selected from the group of fillers and disintegrants are present as excipients which bring about rapid disintegration of the tablet.

11. Dosage form according to Claim 10, characterized in that at least one filler and at least one disintegrant are present.

12. Dosage form according to Claim 11, characterized in that microcrystalline cellulose is present.

13. Dosage form according to Claim 1 to 3, characterized in that one or more further excipients selected from the group of lubricants, aromas, colouring agents, flavourings and surface-active substances are present.

14. Dosage form according to Claim 1, characterized in that the basic excipient is selected from the group of sodium carbonate, calcium carbonate, magnesium carbonates, magnesium oxide, magnesium hydroxide, magnesium metasilicate aluminate, magnesium silicates, magnesium aluminate, hydrotalcite (synthetic), aluminium magnesium hydroxide, and calcium hydroxide, basic salts of amino acids, sodium hydroxide, trihydroxymethylaminomethane, trisodium citrate, disodium hydrogen phosphate and trisodium phosphate or mixtures thereof.

15. Dosage form according to Claim 14, characterized in that sodium carbonate is involved.

16. Dosage form according to Claim 14, characterized in that disodium hydrogen phosphate, trisodium phosphate or buffer systems composed of disodium hydrogen phosphate and sodium hydroxide are involved.

17. Dosage form according to Claim 1, characterized in that a compound selected from the group AU-461, soraprazan (BYK61359), DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 and 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]pyridine-6-carboxamide is present as reversible proton pump inhibitor.

18. Dosage form according to Claim 17, characterized in that (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine (INN soraprazan) or a pharmacologically acceptable salt and/or hydrate thereof is present as proton pump antagonist.

19. Dosage form according to claim 9, comprising (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine (INN soraprazan) or a pharmacologically acceptable salt and/or hydrate thereof as proton pump antagonist, sodium carbonate as basic exipient and microcrystalline cellulose, sodium carboxymethyl starch and magnesium stearate as exipients.

20. Dosage form according to claim 19, which is a film coated tablet.

21. Dosage form according to claim 20, which comprises a coloured film coating.

22. Method for preparing a dosage form according to one of the preceeding claims comprising the step of thoroughly mixing the active ingredient with the basic excipient.

23. Rapidly disintegrating dosage form comprising an effective amount of a proton pump antagonist (APA) together with excipients which, on oral intake of the dosage form, bring about rapid disintegration of the dosage form, and, optionally further excipients.

24. Dosage form according to claim 23, which dosage form shows an immediate release of the proton pump antagonist (APA).

25. Dosage form according to claim 24, which shows a disintegration time determined in water at 37°C of not more than 5 min and a release of active ingredient greater than or equal to 85% after 15 minutes in 0.1 N hydrochloric acid.

26. Dosage form according to Claim 23, characterized in that (7R,8R,9R)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine (INN soraprazan) or a pharmacologically acceptable salt and/or hydrate thereof is present as proton pump antagonist.